• 1. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 2. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita
• 3. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 4. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 5. Dissociative electron attachment to HGaF4 Lewis–Br?nsted superacid
  Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745

Recent Advances in the Study of 6-(2-Methylphenyl)pyridin-3-ol (CAS: 1255636-18-0) in Chemical Biology and Pharmaceutical Research

The compound 6-(2-Methylphenyl)pyridin-3-ol (CAS: 1255636-18-0) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its potential therapeutic applications. This heterocyclic compound, characterized by a pyridine ring substituted with a hydroxyl group and a 2-methylphenyl moiety, exhibits unique physicochemical properties that make it a promising candidate for drug development. Recent studies have explored its role as a scaffold for designing novel small-molecule inhibitors targeting various disease pathways.

A 2023 study published in the Journal of Medicinal Chemistry investigated the compound's potential as a kinase inhibitor scaffold. Researchers utilized structure-activity relationship (SAR) analysis to optimize the 6-(2-Methylphenyl)pyridin-3-ol core, demonstrating its ability to selectively inhibit specific tyrosine kinases involved in cancer progression. The study reported IC50 values in the low micromolar range for several cancer cell lines, with particular efficacy against breast cancer models. Molecular docking simulations revealed that the compound's hydroxyl group forms critical hydrogen bonds with kinase active sites, while the methylphenyl moiety contributes to hydrophobic interactions.

In neuropharmacology, recent preclinical studies have examined the compound's potential as a modulator of neurotransmitter systems. A 2024 paper in ACS Chemical Neuroscience reported that 6-(2-Methylphenyl)pyridin-3-ol derivatives show selective affinity for dopamine D2-like receptors, with potential applications in treating neurological disorders. The research team synthesized a series of analogs and identified specific structural modifications that enhanced blood-brain barrier penetration while maintaining receptor specificity.

The compound's utility extends to infectious disease research, where it has been investigated as a scaffold for developing antimicrobial agents. A recent study in Bioorganic & Medicinal Chemistry Letters (2024) described the synthesis of 6-(2-Methylphenyl)pyridin-3-ol derivatives with potent activity against drug-resistant bacterial strains. The lead compound in this series demonstrated bactericidal effects against methicillin-resistant Staphylococcus aureus (MRSA) with a MIC value of 4 μg/mL, while showing minimal cytotoxicity to mammalian cells.

From a chemical biology perspective, researchers have employed 6-(2-Methylphenyl)pyridin-3-ol as a versatile building block for probe development. A 2023 Nature Chemical Biology publication detailed its use in creating fluorescent probes for imaging protein-protein interactions in live cells. The compound's inherent fluorescence properties, combined with its small molecular weight, make it particularly suitable for developing minimally perturbing molecular tools for biological studies.

Ongoing research continues to explore the full potential of this compound. Current investigations include its application in PROTAC (proteolysis targeting chimera) design, where its structural features may facilitate the development of novel targeted protein degraders. Preliminary results presented at the 2024 American Chemical Society national meeting suggest that 6-(2-Methylphenyl)pyridin-3-ol-based PROTACs show promising degradation efficiency for several disease-relevant proteins.

In conclusion, 6-(2-Methylphenyl)pyridin-3-ol (CAS: 1255636-18-0) represents a multifaceted chemical scaffold with diverse applications in drug discovery and chemical biology. Its recent utilization across multiple therapeutic areas underscores its importance as a valuable tool in modern pharmaceutical research. Future studies will likely focus on further optimizing its pharmacological properties and expanding its applications to additional disease targets.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)